Merit Medical Systems Q3 Earnings Call Highlights
Merit Medical Systems (MMSI) reported a gross margin decline of 81 basis points YoY to 52.8%, citing manufacturing variances and higher costs. The company raised its 2026 non-GAAP EPS outlook to $4.33-$4.37, implying 13-14% growth. It expects 7.9-8.4% GAAP revenue growth and acquired Solo Pace for $45M, adding to its Cardiac Therapies platform. Management noted challenges in China but maintained international growth.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a clear catalyst for the stock, while the acquisition is immaterial to 2026 results but may add incremental earnings in 2027.
Market read
Merit Medical's earnings beat and guidance upgrade create a bullish catalyst for the stock and the broader healthcare device sector.
What to watch
Tariff refunds are delayed until 2027, potentially dampening near‑term cash flow.
Background
Merit Medical Systems reported Q3 results, noting an 81‑bp gross‑margin decline, raised its full‑year EPS outlook, provided Q4 revenue guidance, and announced the acquisition of the remaining equity in Solo Pace for $45 million.
Ticker impact
Merit Medical raised its full-year non‑GAAP EPS outlook to $4.33‑$4.37 and gave Q4 revenue guidance of $418‑$426 million.
likely upward pressure as investors price in higher earnings and revenue expectations
Higher EPS guidance and solid revenue outlook indicate improved profitability, supporting a bullish stance.
Market effects
Improved outlook may boost sentiment across the medical device sector.
Positive for US healthcare and related stocks.
May influence global med‑tech investors and sector ETFs.
Counterpoint
If margin pressure from manufacturing variances persists, upside could be limited.
Key entities
- CompanyMerit Medical Systems
Medical device maker reporting Q3 results and guidance.
- CompanySolo Pace
Temporary pacing systems provider acquired by Merit.
